Fatty Liver - NAFLD - NASH

Dr. Iraj Khosronia

1



2

Also Read: Chronic Liver Disease Signs And Symptoms: Gastroenterologist Tips T Tackle Them

Symptoms of Fatty Liver: To start with, how do we know what are the alarming signs of fatty liver disease? The important thing is that there are no symptoms of the fatty liver at all.

3

North American Fat and Lazy Disease (NAFLD)

COME TO FLORIDA THE FOOD'S GREAT!

Era of Hips and Waists

4






Increasing Importance of NAFLD

5

▶ 1979 **1998** > 1999 > 2002 >2004> 2005 ► Today

8 papers published First NIH conference **First Clinical Trials** > papers published First book on NAFLD/NASH 60 > 354 papers published > 1000 papers published

Prevalence Rates of Obesity in Asia




Demographic Pattern

7

75% patients of NAFLD/NASH are women
All ages are affected – Risk of NASH
with age
Caucasians > Hispanics > Africans > Asians
Indian Fatty Liver – BMI < 25, Non obese,
WC
OSAS increases NASH; Its Rx. Reduces NASH

The Risk Factors

8



NAFLD to NASH – Risk Factors



Age Obesity T2DM SGOT/SGPT

Number represents % of patients with NAFLD on USG who had significant fibrosis on biopsy

What Causes Fatty Liver?



Alcohol
Obesity, 1: WC
T2DM
Triglycerides
Medicines*, TPN

Wilsons's Disease
a-1 Anti-trypsin
Al Hepatitis
Hepatitis C
Inherited synctromes

* MTX, Valp, Acetaminophen, TC, Tamoxifen, Nefidepine, Amiodarone, CCl₄

Clinical Presentation


11

Asymptomatic
Routine blood tests
Liver enzymes
Enlarged Liver (1/3)
RUQ periumb. Pain
Fatigue. Malaise

Anorexia, Nausea
> 90% are obese
USG e/o fatty liver
Acanthosis Nigricans
DM, HTN, Lipid abn.
OSAS, Snoring


NAFLD – Symptoms

12



NAFLD - Clinical Findings





Take Home Points



 \blacktriangleright It is the main cause of \uparrow liver enzymes; Isn't that benign Spectrum of disease – NATLD – NASH – Cirrhosis – HCC Insulin resistance, MS are the key pathogenic features DM, TG, Non failty abdominal obesity, increasing age It is a marker of <u>CV Risk</u>. Rx. improve insulin sensitivity Modify underlying metabolic risk factors - diet, exercise Use Mayo scoring to predict NASH (fibrosis). No biopsy

What Tests to Order?

Ht, Wt, BMI, WC
Blood Pressure
OGTT – IR, DM
Fasting Lipid Profile
SB, SGPT, SGOT, AKP, GGT, Serum Proteins Hemogram complete
USG Abdomen
HCV, HBsAg, ANA
Liver Biopsy, CT Abd
F and PP C-peptide
aPTT, PT, body fat

This Tests For


Lipid Profile Glucose SEPT - SGOT hs-CRP 5 minutes lime Finger Rick CHOLESTECH LDX® SYSTEM

- LDX SYSTEM TESTS > • Lipid
- Profile•GLU
 Lipid Profile
- ALT•AST >
- hs-CRP >
- TC+HDL+GLU
- TC+HDL
- TC+GLU
- TC

The Cholestech LDX System brings a wealth of benefits to healthcare professionals and patients. The LDX System delivers the ability to measure a complete lipid profile and glucose, ALT, AST, and hs-CRP and it does it all in 5 minutes per test cassette (6 minutes for hs-CRP).

The accuracy, speed and broad menu of tests available for the Cholestech LDX make it an invaluable tool in the fight against heart disease, diabetes and metabolic syndrome. Best of all, the rapid results allow for immediate

16



Diagnosis of Fatty Liver

18

USG is enough; CT if USG is not informative

Imaging can detect > 33% fat on liver biopsy

Cannot differentiate Steatosis from steatohepatitis

Liver biopsy is usually not needed to diagnose fatty liver

19

Exclude Other Disease

HBV – HBsAg, (HBV DNA) HCV – anti-HCV, (HCV RNA) Autoimmune hepatitis – ANA Alfa-1 anti-trypsin deficiency Wilson's disease Hepatic malignancy Hepatic infection; Biliary disease

Acanthosis Nigricans




Black Pigmentation - Axilla Black Pigmentation - Neck





USG of Fatty Liver











CT - NASH Liver


CT Liver - Normal



Normal Liver









Fatty Liver (Steatosis) – Ballooning








Steato – Hepatitis (Inflam. + Fibrosis)









Mallory Bodies - Hyaline

Cirrhosis (Nodularity & Scarring)







Role of Liver Biopsy

27

Only accurate method of staging and diagnosis,
May convince patient of need for life-style change
NAFLD / NASH generally good prognosis
Key risk factors are addressed without a biopsy
Lack of effective therapy, cost and risk.
If cirrhosis is clinically suspected – biopsy needed

Guidelines for Treatment



Similar to the recommendations for T2DM and IR HTN Dyslipidemia Obesity and Abdominal obesity

Guidelines for Treatment



1. Eat less fat, especially saturated fat 2. Keep blood sugars normal 3. Drink less or no alcohol 4. Exercise regularly Match kilojoules to energy requirement 5. 6. Don't smoke

Therapeutic Approach

30

Control of risk factors
Decrease of 10% in BMI
Diet as already discussed
Aerobic exercise 30 min x 6 days /week
Statins where indicated

Therapeutic Approach

31

If no response after six months
Pt is at higher risk of fibrosis
Mayo Score or Liver biopsy to distinguish Steatosis versus steatohepatitis - prognosis
Add non-evidence based therapy

Treatment Effects



Exercise is the cornerstone of therapy
Benefit of exercise even without weight
Biochemical improvement – liver enzymes
Variable histological improvement
Variable effect on progression to cirrhosis.

Potential Drugs for NAFLD

INSULIN SENSITIZING AGENTS GLITAZONES; METFORMIN LIPID-LOWERING AGENTS CLOFIBRATE; GEMFIBROZIL FUTURE POTENTIAL TREATMENTS **ANTI-FIBROTICS; PROBIOTICS** SILYMARIN; SELENIUM

Membrane-Stabilizing **Urso deoxy cholic Acid Betaine (SAM)** Anti-Oxidants Vitamin E; Vitamin C Lecithin;
-Carotene Vitamin B Complex